Fosfomycin is active in vitro against extensively drug-resistant (XDR) and pandrug-resistant
(PDR) Pseudomonas aeruginosa and Klebsiella pneumoniae carbapenemase-producing …

The treatment of multidrug-resistant (MDR), extensively drug-resistant or pandrug-resistant
non-fermenting Gram-negative bacterial infections constitutes a challenge in an era of few …

Intensive care unit (ICU)-acquired infections as a result of multidrug-resistant Gram-negative
pathogens remain a serious problem in critically ill patients. Adult ICU patients who received …

Objective: To analyze the indications for and the efficacy of parenteral fosfomycin, especially
against multidrug-resistant (MDR) and pan-resistant bacterial infections. Patients and …

Antimicrobial resistance has become one of the greatest threats to public health, with rising
resistance to carbapenems being a particular concern due to the lack of effective and safe …

The advancing antimicrobial drug resistance among Enterobacteriaceae renders the
evaluation of potential novel therapeutic options necessary. We sought to evaluate the in …

Fosfomycin represents a potential last-resort treatment option for infections with certain
multidrug-resistant (MDR) Gram-negative pathogens. We evaluated double-drug …

Fosfomycin, originally named phosphonomycin, was discovered in Spain in 1969. There are
three forms of fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium …

Abstract Purpose In Europe, intravenous fosfomycin (IV) is used particularly in difficult-to-
treat or complex infections, caused by both Gram-positive and Gram-negative pathogens …

We evaluated the antimicrobial activity of fosfomycin against a randomly selected sample of
30 Klebsiella pneumoniae, 30 Pseudomonas aeruginosa, and 30 Acinetobacter baumannii …